Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prospectives and limitations by a novel algorithm

Prospectives and limitations by a novel algorithm Cancer Chemother Pharmacol (2011) 67:1481–1482 DOI 10.1007/s00280-011-1607-y R E PLY TO THE LE TTER Karin Holweger · Hans-Peter Lipp Published online: 20 March 2011 © Springer-Verlag 2011 Dear colleagues, (SD § 17%) and a precision of 16% (SD § 12%). As a consequence, we did not favor the use of the MDRD-4 We have recently proposed a novel algorithm to be more furthermore. Whether the CKI-EPI formula, which has not accurate to calculate individual GFR in cancer patients over been included in our calculations so far, may be of increasing a broad range of constitutive GFR than conventionally used value needs further clinical investigation [4]. formulas [1]. In order to prove potential translation of our Undoubtedly, clinical experience with anticancer drugs results in clinical practice, we chose carboplatin as a very in obese cancer patients remains scarce. Whereas the use of useful anticancer drug because the agent undergoes exten- the unmodiWed Cockcroft–Gault formula cannot be recom- sive glomerular Wltration as unchanged drug. Carboplatin mended in obese patients receiving carboplatin based on AUC measured by the limited sampling method according the severely increased risk for overdosage, modiWcation of to Sorensen et al. was used as a reference to compare the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Prospectives and limitations by a novel algorithm

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/prospectives-and-limitations-by-a-novel-algorithm-ql7R2HRvJK

References (7)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Cancer Research ; Pharmacology/Toxicology
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-011-1607-y
Publisher site
See Article on Publisher Site

Abstract

Cancer Chemother Pharmacol (2011) 67:1481–1482 DOI 10.1007/s00280-011-1607-y R E PLY TO THE LE TTER Karin Holweger · Hans-Peter Lipp Published online: 20 March 2011 © Springer-Verlag 2011 Dear colleagues, (SD § 17%) and a precision of 16% (SD § 12%). As a consequence, we did not favor the use of the MDRD-4 We have recently proposed a novel algorithm to be more furthermore. Whether the CKI-EPI formula, which has not accurate to calculate individual GFR in cancer patients over been included in our calculations so far, may be of increasing a broad range of constitutive GFR than conventionally used value needs further clinical investigation [4]. formulas [1]. In order to prove potential translation of our Undoubtedly, clinical experience with anticancer drugs results in clinical practice, we chose carboplatin as a very in obese cancer patients remains scarce. Whereas the use of useful anticancer drug because the agent undergoes exten- the unmodiWed Cockcroft–Gault formula cannot be recom- sive glomerular Wltration as unchanged drug. Carboplatin mended in obese patients receiving carboplatin based on AUC measured by the limited sampling method according the severely increased risk for overdosage, modiWcation of to Sorensen et al. was used as a reference to compare the

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: Jun 1, 2011

There are no references for this article.